Efficacy of aflibercept (EYLEA (R)) on inhibition of human VEGF in vitro

Schicht M.; Hesse K.; Schroeder H.; Naschberger E.; Lamprecht W.; Garreis F.; Paulsen F. P.; Braeuer L.

首页> 外文期刊>Annals of anatomy =: Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft >Efficacy of aflibercept (EYLEA (R)) on inhibition of human VEGF in vitro

【24h】

Efficacy of aflibercept (EYLEA (R)) on inhibition of human VEGF in vitro

机译：AfliBelcept（Eylea（R））在体外抑制人VEGF的疗效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several serious ophthalmological diseases such as wet age-related macular degeneration (AMD) or diabetic retinopathy. In AMD treatment, aflibercept (tradename EYLEA (R)) is used to deactivate the underlying pathological neovascularisation. Aflibercept is a recombinant fusion protein which binds to vascular endothelial growth factor (VEGF) receptors, thereby inhibiting VEGF pathway activation. VEGF is one of the most important angiogenesis factors.

机译：介绍：血管的病理形成在肿瘤的生长和转移中起着关键作用，也在几种严重的眼科疾病，如潮湿年龄相关的黄斑（AMD）或糖尿病视网膜病变。在AMD治疗中，AfliBercept（商品名Eylea（R））用于去除潜在的病理新生血管化。 AfliBercept是一种重组融合蛋白，其与血管内皮生长因子（VEGF）受体结合，从而抑制VEGF途径活化。 VEGF是最重要的血管生成因子之一。

著录项

来源
《Annals of anatomy =: Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft》 |2017年第2017期|共5页
作者
Schicht M.; Hesse K.; Schroeder H.; Naschberger E.; Lamprecht W.; Garreis F.; Paulsen F. P.; Braeuer L.;
展开▼
作者单位

Friedrich Alexander Univ Erlangen Nurnberg FAU Inst Anat Erlangen Germany;

Friedrich Alexander Univ Erlangen Nurnberg FAU Inst Anat Erlangen Germany;

Friedrich Alexander Univ Erlangen Nurnberg FAU Inst Anat Erlangen Germany;

Friedrich Alexander Univ Erlangen Nurnberg FAU Div Mol &

Expt Surg Dept Surg Erlangen Germany;

Bohlenpl Erlangen Germany;

Friedrich Alexander Univ Erlangen Nurnberg FAU Inst Anat Erlangen Germany;

Friedrich Alexander Univ Erlangen Nurnberg FAU Inst Anat Erlangen Germany;

Friedrich Alexander Univ Erlangen Nurnberg FAU Inst Anat Erlangen Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类人体形态学;
关键词
EYLEA (R); HUVEC; Aflibercept; VEGF; VEGF-trap;

机译：Eylea（R）;Huvec;AfliBercept;VEGF;VEGF-TRAP;

相似文献

外文文献
中文文献
专利

1. Efficacy of aflibercept (EYLEA (R)) on inhibition of human VEGF in vitro [J] . Schicht M., Hesse K., Schroeder H., Annals of anatomy =: Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft . 2017,第期

机译：AfliBelcept（Eylea（R））在体外抑制人VEGF的疗效
2. Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab3 showed superior anti-angiogenic efficacy to Aflibercept (Eylea): a potential therapeutic agent for exudative Age-related macular degeneration (AMD) [J] . Hong Hye Kyoung, Lim Eun Jin, Ryoo Na-Kyung, Investigative ophthalmology & visual science . 2017,第8期

机译：新型糖基化的VEGF诱饵受体融合蛋白，VEGF-GRAB3对AFLIBERCEPT（EYLEA）的抗血管生成功效显示出优异的抗血管生成效果：潜在的治疗剂，用于渗出性年龄相关的黄斑变性（AMD）
3. Sustained anti-VEGF activity of aflibercept (Eylea (TM)) after storage in polycarbonate syringes used for intravitreal injection: a pathway to safety and efficiency in high volume clinics providing intravitreal therapy. [J] . Han Dennis P., Skumatz Christine, Besharse Joseph C., Investigative ophthalmology & visual science . 2018,第9期

机译：用于玻璃体注射液中的聚碳酸酯注射器储存后AfliBelcept（Eylea（TM））的持续抗VEGF活性：高批诊中提供玻璃体疗法的高批诊院安全性和效率的途径。
4. In Vitro Vascularization of Human Microtissues: VEGF profiling and angiogenesis in human connective micro tissues [C] . J. M. Kelm, C. Diaz Sanchez-Bustamante, M. Fussenegger General Meeting of European Society of Animal Cell Technology . 2007

机译：人体微观调节的体外血管化：人类结缔组织的VEGF分析和血管生成
5. Inhibition of Human Immunodeficiency Virus-1 by Iron Chelators: Effect of Iron Chelators on HIV-1 transcription and Estimation of In-vitro Bioavailability Employing Caco-2 Monolayer. [D] . Debebe, Zufan. 2011

机译：铁螯合剂抑制人免疫缺陷病毒-1：铁螯合剂对HIV-1转录的影响以及使用Caco-2单层的体外生物利用度的估计。
6. Safety profiles of anti-VEGF drugs: bevacizumab ranibizumab aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture [O] . Deepika Malik, Mohamed Tarek, Javier Caceres del Carpio, -1

机译：抗VEGF药物：贝伐单抗兰尼单抗阿柏西普和齐夫-阿非贝西普对培养的人视网膜色素上皮细胞的安全性
7. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture [O] . Deepika Malik, Mohamed Tarek, Javier Caceres del Carpio, 2014

机译：抗VEGF药物的安全概况：Bevacizumab，Ranibizumab，Aflibercept和Ziv-Aflibercept在人类视网膜色素上皮细胞中培养

Efficacy of aflibercept (EYLEA (R)) on inhibition of human VEGF in vitro

摘要

著录项

相似文献

相关主题

期刊订阅